Retatrutide primarily influences metabolic and appetite-regulating pathways via incretin and glucagon signalling, whilst sermorelin operates through the hypothalamic-pituitary-somatotropic axis
Wherever you are, diet culture is there, Previte says
Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease
Sustainable Weight Loss Clinical studies show an average of 15% body weight reduction over 68 weeks when combined with lifestyle changes
GLP-1 medications are expensive, with monthly costs ranging from $900 to $1,300 without insurance coverage
Retatrutide is an investigational triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, enhancing insulin secretion, suppressing appetite, increasing energy expenditure, and promoting hepatic fat oxidation